- Home
- NXU vs THAR Comparison
NXU vs THAR Comparison
Compare NXU & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXU
- THAR
- Stock Information
- Founded
- NXU 2016
- THAR 2017
- Country
- NXU United States
- THAR United States
- Employees
- NXU N/A
- THAR N/A
- Industry
- NXU Automotive Aftermarket
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- NXU Consumer Discretionary
- THAR Health Care
- Exchange
- NXU Nasdaq
- THAR Nasdaq
- Market Cap
- NXU 2.9M
- THAR 2.8M
- IPO Year
- NXU 2022
- THAR 2022
- Fundamental
- Price
- NXU $0.33
- THAR $2.17
- Analyst Decision
- NXU
- THAR
- Analyst Count
- NXU 0
- THAR 0
- Target Price
- NXU N/A
- THAR N/A
- AVG Volume (30 Days)
- NXU 21.3M
- THAR 3.3M
- Earning Date
- NXU 11-26-2024
- THAR 11-07-2024
- Dividend Yield
- NXU N/A
- THAR N/A
- EPS Growth
- NXU N/A
- THAR N/A
- EPS
- NXU N/A
- THAR N/A
- Revenue
- NXU $396,000.00
- THAR N/A
- Revenue This Year
- NXU N/A
- THAR N/A
- Revenue Next Year
- NXU N/A
- THAR N/A
- P/E Ratio
- NXU N/A
- THAR N/A
- Revenue Growth
- NXU 238.46
- THAR N/A
- 52 Week Low
- NXU $0.21
- THAR $1.84
- 52 Week High
- NXU $5.70
- THAR $79.50
- Technical
- Relative Strength Index (RSI)
- NXU 43.37
- THAR 44.85
- Support Level
- NXU $0.34
- THAR $1.90
- Resistance Level
- NXU $0.43
- THAR $2.33
- Average True Range (ATR)
- NXU 0.07
- THAR 0.54
- MACD
- NXU -0.03
- THAR -0.04
- Stochastic Oscillator
- NXU 18.15
- THAR 6.22
About NXU Nxu Inc.
Nxu Inc is a technology company developing next-generation electric vehicle (EV) charging, battery, and vehicle technologies for mobility customers. Its technology company building energy and infrastructure solutions for consumers and businesses. Its NxuOne charging technology provides repeatable, consistent power delivery, designed to meet the needs of today's electric vehicles as well as those developed in the future.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.